A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Czechia- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to Czechia1 231 clinical trials in Prague, Czechia across 17 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in CzechiaKlinickeTesty.cz(opens in a new tab)
CzechiaLong‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis
CzechiaPhase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer
CzechiaStudy of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)
CzechiaPhase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2
CzechiaPhase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1
CzechiaLong-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa
CzechiaLong-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis
CzechiaA study to evaluate the safety and effectiveness of dextromethorphan, deramciclane fumarate, and deramciclane in treating agitation in people with Alzheimer's disease
CzechiaA study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer
CzechiaA Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety
CzechiaA Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis
CzechiaThe busiest research cities in the country
What the registry says about research in the country
Clinical trial activity in Praha includes research in advanced melanoma and diffuse large B-cell lymphoma, with a strong focus on improving cancer control and extending survival.
These studies are designed to refine how immunotherapy and other cancer treatments perform in everyday clinical care.
Research in cardiovascular diseases is centered on reducing major heart and vascular events, with trials looking at hypertension, atherosclerotic cardiovascular disease, and heart failure prevention.
Several studies aim to improve treatment effectiveness for patients at elevated cardiovascular risk.
Trials in the respiratory field focus on better symptom control and fewer flare-ups in chronic obstructive pulmonary disease, alongside ongoing work in infection-related lung illness.
These studies support more effective care for both chronic and acute respiratory conditions.
Dermatology research in Czechia includes several inflammatory skin disorders, with studies targeting itch, lesion control, and long-term disease management.
The goal is to evaluate new therapies that may ease symptoms and improve quality of life.
Studies in immune-mediated disease are exploring treatments that can calm abnormal inflammation while maintaining safety and tolerability.
These trials aim to improve control of chronic immune-driven disease burden.
Neurology-related research focuses on agitation in Alzheimer's disease dementia, with efforts to better manage behavioral symptoms that affect patients and caregivers.
These studies may help support more practical care for people living with dementia.
Metabolic research in Praha includes trials for overweight, obesity, and related conditions, often linked with cardiovascular risk.
These studies are testing approaches that may help reduce long-term health risks tied to excess weight.
In the area of virus diseases, research is centered on improving treatment options for people with COVID-19 who are at higher risk of becoming seriously ill.
The main aim is to help prevent worsening disease and support faster recovery.
Tell us about your condition – we search every trial in Europe and connect you with the right site.